Market Overview

UPDATE: JP Morgan Downgrades United Therapeutics to Underweight

Share:
Related UTHR
Biotech: Anatomy Of An Investing Mania?
5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co. (Seeking Alpha)

JP Morgan reduced its rating on United Therapeutics (NASDAQ: UTHR) from Neutral to Underweight and lowered its price target from $50 to $40.

JP Morgan commented, "We're moving to Underweight from Neutral on UTHR shares and lowering our Dec 2013 target to $40 from $50 on the back of yesterday's complete response letter (CRL) by FDA on oral Remodulin. While we recognize that oral Remodulin wasn't assumed in a lot of Street models (including ours), it was somewhat reflected in valuation and is it essentially the company's only upside driver over a 2+ year period. Given the rationale for the CRL, it doesn't seem to us that oral is approvable in the US or EU, at least not in the next 3-4 years."

United Therapeutics closed at $53.28 on Tuesday.

Latest Ratings for UTHR

DateFirmActionFromTo
Apr 2015JP MorganMaintainsNeutral
Mar 2015Argus ResearchUpgradesHoldBuy
Feb 2015JefferiesMaintainsHold

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (UTHR)

Around the Web, We're Loving...